(Q48705555)

English

Randomised clinical trial: delayed-release oral mesalazine 4.8 g/day vs. 2.4 g/day in endoscopic mucosal healing--ASCEND I and II combined analysis.

scientific article published on 23 January 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

14 February 2018

http://europepmc.org/abstract/MED/21255059

0 references

Randomised clinical trial: delayed-release oral mesalazine 4.8 g/day vs. 2.4 g/day in endoscopic mucosal healing--ASCEND I and II combined analysis. (English)

1 reference

Europe PubMed Central

14 February 2018

http://europepmc.org/abstract/MED/21255059

author name string

G R Lichtenstein

1

1 reference

Europe PubMed Central

14 February 2018

http://europepmc.org/abstract/MED/21255059

D Ramsey

2

1 reference

Europe PubMed Central

14 February 2018

http://europepmc.org/abstract/MED/21255059

D T Rubin

3

1 reference

Europe PubMed Central

14 February 2018

http://europepmc.org/abstract/MED/21255059

language of work or name

0 references

publication date

23 January 2011

1 reference

Europe PubMed Central

14 February 2018

http://europepmc.org/abstract/MED/21255059

Alimentary Pharmacology & Therapeutics

1 reference

Europe PubMed Central

14 February 2018

http://europepmc.org/abstract/MED/21255059

33

1 reference

Europe PubMed Central

14 February 2018

http://europepmc.org/abstract/MED/21255059

6

1 reference

Europe PubMed Central

14 February 2018

http://europepmc.org/abstract/MED/21255059

672-678

1 reference

Europe PubMed Central

14 February 2018

http://europepmc.org/abstract/MED/21255059

Ulcerative Colitis Practice Guidelines in Adults (Update): American College of Gastroenterology, Practice Parameters Committee

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04575.X

21 January 2018

Infliximab for induction and maintenance therapy for ulcerative colitis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04575.X

21 January 2018

Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04575.X

21 January 2018

Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04575.X

21 January 2018

Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04575.X

21 January 2018

Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04575.X

21 January 2018

Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04575.X

21 January 2018

The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04575.X

21 January 2018

The inflammatory bowel disease questionnaire: a valid and reliable measure in ulcerative colitis patients in the North East of England

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04575.X

21 January 2018

Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04575.X

21 January 2018

Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04575.X

21 January 2018

Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04575.X

21 January 2018

Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04575.X

21 January 2018

Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04575.X

21 January 2018

Importance of mucosal healing in ulcerative colitis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2010.04575.X

21 January 2018

Identifiers

10.1111/J.1365-2036.2010.04575.X

1 reference

Europe PubMed Central

14 February 2018

http://europepmc.org/abstract/MED/21255059

1 reference

Europe PubMed Central

14 February 2018

http://europepmc.org/abstract/MED/21255059

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48705555&oldid=1209083761"